Source: National Center for nanoscience 13:00, May 6, 2020

Participating in the research activity of the International Symposium on cell therapy (the 11th session) in 2020

Recently, the journal Nature Nanotechnology published online the new progress of Wang Lei, researcher of national Nano Science Center, and kit Lam, Professor of University of California, Davis, on the treatment of HER2 positive breast cancer. The title of this paper is transformable HER2 targeting Nanoparticals arest HER2 signaling leading to tumour death in vivo. The researchers use deformable polypeptide nanoparticles to construct polypeptide nanofiber network by biomimetic extracellular matrix, which can achieve better tumor treatment effect and promote the transformation process of polypeptide nanodrugs.

In this study, in combination with the previous work of biomimetic polypeptide (ACS Nano, 2017, 114086-4096), the researchers designed polypeptide molecules targeting HER2 and forming extracellular matrix like nanofiber network, and successfully constructed the fiber network in HER2 positive breast cancer cells by using the deformation induced by ligand receptor interaction and the biomimetic process of self amplification assembly. The nano polypeptide drug is very effective in the treatment of HER2 positive breast cancer model mice. After treatment, the tumor in mice gradually reduced to complete disappearance, and the survival period of model mice greatly prolonged (nature nanotech., 2020, 15145 – 153).

Kit Lam is an expert in peptide field. He once served as the director of Hematology Oncology Department. Later, he established the Department of Biochemistry and molecular medicine and served as the director. The OBOC invented by him can be widely used in the screening of bioactive peptides (nature, 1991354, 82 – 84).

This work is based on the in vivo self-assembly concept proposed by Wang Hao group of national nano center. Previous work has shown that the transformation of polypeptide nanoparticles into nanofibers can be realized in tumor tissues of model mice through the regulation of hydrophobic balance, and the retention time is significantly increased (adv. mater., 2017, 291605869).

The mechanism of the nanopeptide drug is universal, and a series of bionic nanopeptide drugs can be developed by using the existing membrane protein drug targets. The author has applied for related invention patents. It needs to be pointed out again that the above antitumor effects are mainly based on the in vivo experiments of tumor mouse models, and there is a long way to go from laboratory animal models to clinical transformation applications.